-- 加拿大統計局週四表示,2月加拿大實際國內生產毛額(GDP)季增0.2%,商品生產業連續第二個月推動經濟成長。 2月份的GDP成長與三菱日聯銀行(MUFG)提供的共識數據完全一致。 加拿大統計局在聲明中指出,初步數據顯示,3月份實際GDP「基本上保持不變」。批發貿易和運輸倉儲業的成長被零售貿易以及採礦、採石、石油和天然氣開採業的下降所抵消。 加拿大統計局表示,根據3月份的初步估計,按行業劃分的實際GDP資訊表明,2026年第一季加拿大經濟成長了0.4%。 這家位於渥太華的機構補充說,2月份商品生產行業環比增長0.4%,主要受製造業以及採礦、採石、石油和天然氣開採業擴張的推動。服務業小幅成長0.1%,其中運輸、倉儲和批發貿易的反彈基本上被公共部門的萎縮所抵消。 對加拿大而言,國內生產毛額(GDP)和收支帳戶衡量加拿大經濟中商品和服務的生產,以及由此產生的收入和支出。 GDP代表參考期間生產的、可用於國內消費、投資或出口的商品和服務的不重複計算價值。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%